Cytodyn Inc (CYDY)

[justdafactss]

SANTA FE, NM (PRWEB) OCTOBER 22, 2008

CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
Share Article

CytoDyn, Inc. is preparing for its next clinical trial of Cytolin, the breakthrough drug for HIV/AIDS that uses the body's own immune system to fight the virus. The preparations come at a time when CytoDyn, Inc. is making big changes that include relocating to a larger facility to accommodate expanded business activities.
https://www.prweb.com/releases/cytolin/clinical-trial/prweb1501134.htm

Cytolin: hype-driven therapy

AIDS: The public and the media are interested in Cytolin, an immune-based therapy unapproved by the Food and Drug Administration (FDA). Cytolin consists of a specific antibody derived from mice. The antibody recognizes and binds to a specific protein, S6F1. Adverse reactions from a nonhuman protein-based substance, ranging from flu-like symptoms to anaphylactic reactions, have occurred. Critics warn that Cytolin can neutralize the role that S6F1-marked cells play in killing virus-infected cells. Advocates claim that improvements in immune responses have occurred in treated patients with early HIV. The evidence is anecdotal and hard to judge. Scientific trials have begun and are expected to continue next summer.
https://pubmed.ncbi.nlm.nih.gov/11362995/